Sai Life Sciences Q1 FY27 Standalone Profit Rs. 713.39 million
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 06 Aug 2026, 10:26 PM IST · BSE ID: d809401b-0083-4973-b6ae-b413a0d6de7e
View Original BSE Filing (PDF)
💡
In Simple Terms
Sai Life Sciences announced its latest quarterly financial results, showing profit and revenue for the period ending June 2026.
🤖 AI Summary
- Sai Life Sciences Board approved Q1 FY27 unaudited standalone financial results for quarter ended June 30, 2026.
- Standalone profit for the period was Rs. 713.39 million, with revenue from operations at Rs. 5,467.29 million.
- Consolidated profit for the period was Rs. 714.47 million, on revenue from operations of Rs. 5,542.85 million.
- Company allotted 506,782 equity shares of Rs. 1 each due to employee stock option exercises during Q1 FY27.
- Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified conclusion on the limited review.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from operations (Q1 FY27)
5,467.29 million
13.18
Standalone Profit for the period (Q1 FY27)
713.39 million
22.23
Consolidated Revenue from operations (Q1 FY27)
5,542.85 million
11.66
Consolidated Profit for the period (Q1 FY27)
714.47 million
19.95
Standalone Basic EPS (Q1 FY27)
3.36
20.00
🏢 How This Affects the Company
The company continues its operations in Contract Research, Development and Manufacturing Services (CRDMO) as its single segment, aligning with its established business model.
Standalone profit for the quarter was Rs. 713.39 million, a 22.23% increase year-on-year from Rs. 583.70 million in Q1 FY26. Consolidated profit reached Rs. 714.47 million, growing 19.95% from Rs. 595.63 million.
The exercise of employee stock options indicates ongoing employee engagement and retention strategies, leading to an increase in paid-up equity share capital to Rs. 212.29 million.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results disclosure.
👤
Who Is Affected
Existing shareholders are affected by the financial performance, specifically the 22.23% year-on-year increase in standalone profit for the period and the 19.95% rise in consolidated profit. The allotment of 506,782 new equity shares impacts ownership percentages marginally.
🔍
Management Signal
The approval of financial results and the unmodified limited review report signal management's adherence to regulatory disclosure requirements and financial reporting standards.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results — check revenue and profit trends.
Updates on new project wins or capacity expansion plans.
Any further clarification from the Government on Labour Codes impact.
LOW RISK
The filing reports stable financial results with year-on-year profit growth and an unmodified audit conclusion.
💡 Investor Takeaway
Sai Life Sciences reported Q1 FY27 standalone profit of Rs. 713.39 million, a 22.23% increase from Rs. 583.70 million in Q1 FY26. Consolidated profit stood at Rs. 714.47 million, up 19.95% from Rs. 595.63 million in the prior year.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Profit for the period increased to Rs. 713.39 million in Q1 FY27, up 22.23% from Rs. 583.70 million in Q1 FY26.
- Consolidated Profit for the period rose to Rs. 714.47 million in Q1 FY27, a 19.95% increase from Rs. 595.63 million in Q1 FY26.
⚠️ Concerns
- Standalone Revenue from operations decreased to Rs. 5,467.29 million in Q1 FY27 from Rs. 5,943.40 million in Q4 FY26.
- Consolidated Revenue from operations decreased to Rs. 5,542.85 million in Q1 FY27 from Rs. 6,021.39 million in Q4 FY26.
📅 Company Track Record
Sai Life Sciences' FY26 net profit (PAT) increased 109% to ₹355 Cr, with revenue up 29% to ₹2,192 Cr as of the May 14, 2026 filing. The audited FY26 profit surged 96.86% to Rs. 3,414.81 million. This Q1 FY27 filing builds on that performance.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Sai Life Sciences' standalone net profit for Q1 FY27?
Sai Life Sciences reported a standalone net profit for the period of Rs. 713.39 million for the quarter ended June 30, 2026.
What was the consolidated revenue from operations for Sai Life Sciences in Q1 FY27?
The consolidated revenue from operations for Sai Life Sciences was Rs. 5,542.85 million for the quarter ended June 30, 2026.
How many new equity shares did Sai Life Sciences allot during Q1 FY27?
Sai Life Sciences allotted 506,782 equity shares of Rs. 1 each during the quarter ended June 30, 2026, due to employee stock option exercises.
What was the year-on-year growth in standalone profit for Sai Life Sciences in Q1 FY27?
Standalone profit for the period increased by 22.23% to Rs. 713.39 million in Q1 FY27 compared to Rs. 583.70 million in Q1 FY26.
What conclusion did the statutory auditors provide for the Q1 FY27 results?
Deloitte Haskins & Sells LLP, the statutory auditors, issued an unmodified conclusion in their limited review for the quarter ended June 30, 2026.
Questions based on this BSE filing only. For information purposes.